Invesco Ltd. Apellis Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 604,113 shares of APLS stock, worth $18.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

604,113

Previous 1,102,833 45.22%

Holding current value

$18.6 Million

Previous $42.3 Million 58.82%

% of portfolio

0.0%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$28.84 - $41.15 $14.4 Million - $20.5 Million	-498,720 Reduced 45.22%	604,113 $17.4 Million
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $13 Million - $20.3 Million	340,718 Added 44.71%	1,102,833 $42.3 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $13.5 Million - $17.6 Million	243,278 Added 46.89%	762,115 $44.8 Million
Q4 2023 Feb 12, 2024	SELL	$37.14 - $64.82 $811,100 - $1.42 Million	-21,839 Reduced 4.04%	518,837 $31.1 Million
Q3 2023 Nov 13, 2023	SELL	$23.65 - $89.22 $14.5 Million - $54.6 Million	-611,720 Reduced 53.08%	540,676 $20.6 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $8.54 Million - $10.4 Million	111,415 Added 10.7%	1,152,396 $105 Million
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $25.2 Million - $36.2 Million	540,194 Added 107.87%	1,040,981 $68.7 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $4.43 Million - $6.25 Million	-102,466 Reduced 16.99%	500,787 $25.9 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $19.2 Million - $29.9 Million	429,625 Added 247.44%	603,253 $41.2 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $1.42 Million - $2.39 Million	40,445 Added 30.37%	173,628 $7.85 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $3 Million - $4.58 Million	84,634 Added 174.33%	133,183 $6.77 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $190,249 - $304,251	-6,189 Reduced 11.31%	48,549 $2.3 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $17 Million - $37.9 Million	-542,178 Reduced 90.83%	54,738 $1.8 Million
Q2 2021 Aug 17, 2021	BUY	$40.9 - $64.9 $2.32 Million - $3.69 Million	56,809 Added 10.52%	596,916 $37.7 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $856,187 - $1.2 Million	-20,985 Reduced 3.74%	540,107 $23.2 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $5.1 Million - $9.48 Million	-165,685 Reduced 22.8%	561,092 $32.1 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $4 Million - $5.2 Million	154,664 Added 27.03%	726,777 $21.9 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $5.32 Million - $8.25 Million	214,437 Added 59.95%	572,113 $18.7 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $6.41 Million - $15.9 Million	357,676 New	357,676 $9.58 Million
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $982,366 - $1.31 Million	-40,779 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $734,022 - $1.03 Million	40,779 New	40,779 $1.03 Million

Others Institutions Holding APLS

# of Institutions

309

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.38B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account